# Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

> **NCT01269853** · PHASE1,PHASE2 · RECRUITING · sponsor: **Northwell Health** · enrollment: 54 (estimated)

## Conditions studied

- Glioblastoma Multiforme
- Anaplastic Astrocytoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01269853
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2010-10
- **Primary completion:** 2026-10
- **Final completion:** 2027-10
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01269853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01269853, "Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01269853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*